Advertisement
CytomX Therapeutics, Inc. (CTMX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
As of 02:01PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 1.4100 |
| Open | 1.3700 |
| Bid | 1.4400 x 1000 |
| Ask | 1.4500 x 3200 |
| Day's Range | 1.3700 - 1.4599 |
| 52 Week Range | 1.0400 - 3.0200 |
| Volume | |
| Avg. Volume | 173,966 |
| Market Cap | 96.799M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | Nov 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.61 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for CTMX
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- CytomX Therapeutics, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat3 days agoMorningstar
ZacksAstraZeneca (AZN) to Discontinue Two Studies on Lokelma
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
ZacksAnnovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
ZacksAbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.